Accumulation of driver and passenger mutations during tumor progression.

Cancer genome landscapes. Science (2013) 25.33

Clonal evolution in cancer. Nature (2012) 11.07

Intra-tumour heterogeneity: a looking glass for cancer? Nat Rev Cancer (2012) 6.82

A Big Bang model of human colorectal tumor growth. Nat Genet (2015) 3.77

Recurrent hemizygous deletions in cancers may optimize proliferative potential. Science (2012) 3.41

HIV latency. Proliferation of cells with HIV integrated into cancer genes contributes to persistent infection. Science (2014) 3.17

Half or more of the somatic mutations in cancers of self-renewing tissues originate prior to tumor initiation. Proc Natl Acad Sci U S A (2013) 3.15

Origins of metastatic traits. Cancer Cell (2013) 2.49

A remarkably simple genome underlies highly malignant pediatric rhabdoid cancers. J Clin Invest (2012) 2.42

Temporal dissection of tumorigenesis in primary cancers. Cancer Discov (2011) 2.40

Impact of deleterious passenger mutations on cancer progression. Proc Natl Acad Sci U S A (2013) 2.23

TGF-β: duality of function between tumor prevention and carcinogenesis. J Natl Cancer Inst (2014) 2.08

Mutations driving CLL and their evolution in progression and relapse. Nature (2015) 2.06

Cancer biomarkers: selecting the right drug for the right patient. Nat Rev Drug Discov (2012) 1.96

Metastatic stem cells: sources, niches, and vital pathways. Cell Stem Cell (2014) 1.88

A spatial model predicts that dispersal and cell turnover limit intratumour heterogeneity. Nature (2015) 1.66

Chromothripsis and beyond: rapid genome evolution from complex chromosomal rearrangements. Genes Dev (2013) 1.61

Plasticity of tumour and immune cells: a source of heterogeneity and a cause for therapy resistance? Nat Rev Cancer (2013) 1.61

Mutant proteins as cancer-specific biomarkers. Proc Natl Acad Sci U S A (2011) 1.56

Prediagnostic serum biomarkers as early detection tools for pancreatic cancer in a large prospective cohort study. PLoS One (2014) 1.55

Clonal evolution in hematological malignancies and therapeutic implications. Leukemia (2013) 1.50

miR-23a promotes the transition from indolent to invasive colorectal cancer. Cancer Discov (2012) 1.49

A recellularized human colon model identifies cancer driver genes. Nat Biotechnol (2016) 1.47

NCI's provocative questions on cancer: some answers to ignite discussion. Oncotarget (2011) 1.42

Extrachromosomal oncogene amplification drives tumour evolution and genetic heterogeneity. Nature (2017) 1.42

Cancer evolution: mathematical models and computational inference. Syst Biol (2014) 1.36

Intratumor heterogeneity in evolutionary models of tumor progression. Genetics (2011) 1.31

Molecular damage in cancer: an argument for mTOR-driven aging. Aging (Albany NY) (2011) 1.29

Systemic buffers inhibit carcinogenesis in TRAMP mice. J Urol (2012) 1.28

Evolution and dynamics of pancreatic cancer progression. Oncogene (2013) 1.25

Identification of neutral tumor evolution across cancer types. Nat Genet (2016) 1.25

Extremely high genetic diversity in a single tumor points to prevalence of non-Darwinian cell evolution. Proc Natl Acad Sci U S A (2015) 1.24

TrAp: a tree approach for fingerprinting subclonal tumor composition. Nucleic Acids Res (2013) 1.23

Accurate reconstruction of the temporal order of mutations in neoplastic progression. Cancer Prev Res (Phila) (2011) 1.21

The temporal order of genetic and pathway alterations in tumorigenesis. PLoS One (2011) 1.20

Harnessing the antigenic fingerprint of each individual cancer for immunotherapy of human cancer: genomics shows a new way and its challenges. Cancer Immunol Immunother (2013) 1.19

Cancer in light of experimental evolution. Curr Biol (2012) 1.17

Systematic identification of cancer driving signaling pathways based on mutual exclusivity of genomic alterations. Genome Biol (2015) 1.14

Advances for studying clonal evolution in cancer. Cancer Lett (2013) 1.14

The head and neck cancer cell oncogenome: a platform for the development of precision molecular therapies. Oncotarget (2014) 1.12

Cancer heterogeneity--a multifaceted view. EMBO Rep (2013) 1.11

Stochastic modeling indicates that aging and somatic evolution in the hematopoetic system are driven by non-cell-autonomous processes. Aging (Albany NY) (2014) 1.08

Dynamics of targeted cancer therapy. Trends Mol Med (2012) 1.07

Translating cancer 'omics' to improved outcomes. Genome Res (2012) 1.07

Modelling the evolution of genetic instability during tumour progression. Evol Appl (2012) 1.04

Tug-of-war between driver and passenger mutations in cancer and other adaptive processes. Proc Natl Acad Sci U S A (2014) 1.03

Amplified genes may be overexpressed, unchanged, or downregulated in cervical cancer cell lines. PLoS One (2012) 1.03

Spatial structure increases the waiting time for cancer. New J Phys (2011) 1.02

Germline fitness-based scoring of cancer mutations. Genetics (2011) 1.02

Chemokine 25-induced signaling suppresses colon cancer invasion and metastasis. J Clin Invest (2012) 1.01

Proteomic consequences of a single gene mutation in a colorectal cancer model. J Proteome Res (2011) 1.01

Cancer Systems Biology: a peek into the future of patient care? Nat Rev Clin Oncol (2014) 1.01

CanDrA: cancer-specific driver missense mutation annotation with optimized features. PLoS One (2013) 1.00

The mathematics of cancer: integrating quantitative models. Nat Rev Cancer (2015) 1.00

DriverDB: an exome sequencing database for cancer driver gene identification. Nucleic Acids Res (2013) 0.99

Toward an evolutionary model of cancer: Considering the mechanisms that govern the fate of somatic mutations. Proc Natl Acad Sci U S A (2015) 0.99

Delving into somatic variation in sporadic melanoma. Pigment Cell Melanoma Res (2012) 0.99

Cell motility and drug gradients in the emergence of resistance to chemotherapy. Proc Natl Acad Sci U S A (2013) 0.99

High DNA methylation pattern intratumoral diversity implies weak selection in many human colorectal cancers. PLoS One (2011) 0.98

RET is a potential tumor suppressor gene in colorectal cancer. Oncogene (2012) 0.98

Pancreatic cancer biology and genetics from an evolutionary perspective. Nat Rev Cancer (2016) 0.98

MicroRNA-224 negatively regulates p21 expression during late neoplastic progression in inflammatory bowel disease. Inflamm Bowel Dis (2013) 0.97

Evolutionary triage governs fitness in driver and passenger mutations and suggests targeting never mutations. Nat Commun (2014) 0.97

POPULATION GENETICS OF NEUTRAL MUTATIONS IN EXPONENTIALLY GROWING CANCER CELL POPULATIONS. Ann Appl Probab (2013) 0.97

Dynamics of preventive vs post-diagnostic cancer control using low-impact measures. Elife (2015) 0.97

A general framework for analyzing tumor subclonality using SNP array and DNA sequencing data. Genome Biol (2014) 0.96

Do mutator mutations fuel tumorigenesis? Cancer Metastasis Rev (2013) 0.96

Towards a molecular basis of oligometastatic disease: potential role of micro-RNAs. Clin Exp Metastasis (2014) 0.96

Spatial heterogeneity in drug concentrations can facilitate the emergence of resistance to cancer therapy. PLoS Comput Biol (2015) 0.96

Deep sequencing as a probe of normal stem cell fate and preneoplasia in human epidermis. Proc Natl Acad Sci U S A (2015) 0.96

Unbiased metabolite profiling indicates that a diminished thymidine pool is the underlying mechanism of colon cancer chemoprevention by alpha-difluoromethylornithine. Cancer Discov (2013) 0.95

Stochastic dynamics and the evolution of mutations in stem cells. BMC Biol (2011) 0.95

Inference of tumor phylogenies from genomic assays on heterogeneous samples. J Biomed Biotechnol (2012) 0.94

Concepts in solid tumor evolution. Trends Genet (2015) 0.94

Structural bioinformatics of the interactome. Annu Rev Biophys (2014) 0.93

ARID1B, a member of the human SWI/SNF chromatin remodeling complex, exhibits tumour-suppressor activities in pancreatic cancer cell lines. Br J Cancer (2013) 0.93

Advantages of genomic complexity: bioinformatics opportunities in microRNA cancer signatures. J Am Med Inform Assoc (2011) 0.93

Complex role of space in the crossing of fitness valleys by asexual populations. J R Soc Interface (2014) 0.93

Reconstructing metastatic seeding patterns of human cancers. Nat Commun (2017) 0.92

Multi-target stool DNA test: a new high bar for noninvasive screening. Dig Dis Sci (2014) 0.91

Preventive evolutionary medicine of cancers. Evol Appl (2012) 0.91

Distinctive properties of metastasis-initiating cells. Genes Dev (2016) 0.91

Mouse models for colorectal cancer. Am J Cancer Res (2013) 0.91

Bioinformatics for cancer immunology and immunotherapy. Cancer Immunol Immunother (2012) 0.90

The early history of tumor virology: Rous, RIF, and RAV. Proc Natl Acad Sci U S A (2011) 0.90

The effect of one additional driver mutation on tumor progression. Evol Appl (2012) 0.90

A gene expression signature distinguishes normal tissues of sporadic and radiation-induced papillary thyroid carcinomas. Br J Cancer (2012) 0.90

Identifying early events of gene expression in breast cancer with systems biology phylogenetics. Cytogenet Genome Res (2013) 0.88

Exome sequencing identifies MXRA5 as a novel cancer gene frequently mutated in non-small cell lung carcinoma from Chinese patients. Carcinogenesis (2012) 0.88

The novel chemical entity YTR107 inhibits recruitment of nucleophosmin to sites of DNA damage, suppressing repair of DNA double-strand breaks and enhancing radiosensitization. Clin Cancer Res (2011) 0.88

Evaluation of current cancer immunotherapy: hemato-oncology. Cancer J (2011) 0.88

The mini-driver model of polygenic cancer evolution. Nat Rev Cancer (2015) 0.87

A deterministic model for the occurrence and dynamics of multiple mutations in hierarchically organized tissues. J R Soc Interface (2013) 0.87

The clinical, research, and social value of autopsy after any cancer death: a perspective from the Children's Oncology Group Soft Tissue Sarcoma Committee. Cancer (2011) 0.87

The structural impact of cancer-associated missense mutations in oncogenes and tumor suppressors. Mol Cancer (2011) 0.87

Senescent cells in growing tumors: population dynamics and cancer stem cells. PLoS Comput Biol (2012) 0.87

Identification of novel metastasis suppressor signaling pathways for breast cancer. Cell Cycle (2012) 0.86

Stochastic Hypothesis of Transition from Inborn Neutropenia to AML: Interactions of Cell Population Dynamics and Population Genetics. Front Oncol (2013) 0.86

Quantifying Clonal and Subclonal Passenger Mutations in Cancer Evolution. PLoS Comput Biol (2016) 0.86

A high-content cellular senescence screen identifies candidate tumor suppressors, including EPHA3. Cell Cycle (2013) 0.85

The consensus coding sequences of human breast and colorectal cancers. Science (2006) 60.02

An integrated genomic analysis of human glioblastoma multiforme. Science (2008) 51.36

The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol (2007) 49.11

Patterns of somatic mutation in human cancer genomes. Nature (2007) 38.41

DNA sequencing of a cytogenetically normal acute myeloid leukaemia genome. Nature (2008) 38.13

The genomic landscapes of human breast and colorectal cancers. Science (2007) 38.12

Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science (2008) 36.02

Recurring mutations found by sequencing an acute myeloid leukemia genome. N Engl J Med (2009) 33.09

Mutation and cancer: statistical study of retinoblastoma. Proc Natl Acad Sci U S A (1971) 31.05

Cancer genes and the pathways they control. Nat Med (2004) 24.22

Genetic instabilities in human cancers. Nature (1998) 22.76

The Universal Protein Resource (UniProt) in 2010. Nucleic Acids Res (2009) 19.70

Comparative lesion sequencing provides insights into tumor evolution. Proc Natl Acad Sci U S A (2008) 10.52

COSMIC (the Catalogue of Somatic Mutations in Cancer): a resource to investigate acquired mutations in human cancer. Nucleic Acids Res (2009) 9.59

The evolution of cancer of the colon and rectum. Cancer (1975) 9.05

Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis. N Engl J Med (1993) 6.13

Mutation and cancer: a model for human carcinogenesis. J Natl Cancer Inst (1981) 5.59

Cancer-specific high-throughput annotation of somatic mutations: computational prediction of driver missense mutations. Cancer Res (2009) 4.92

The age distribution of cancer and a multi-stage theory of carcinogenesis. 1954. Int J Epidemiol (2004) 4.66

Mapping the cancer genome. Pinpointing the genes involved in cancer will help chart a new course across the complex landscape of human malignancies. Sci Am (2007) 4.66

Genetic progression and the waiting time to cancer. PLoS Comput Biol (2007) 3.57

The role of chromosomal instability in tumor initiation. Proc Natl Acad Sci U S A (2002) 3.46

Primary chemoprevention of familial adenomatous polyposis with sulindac. N Engl J Med (2002) 3.16

Evolution of resistance during clonal expansion. Genetics (2006) 2.36

Direct correlation between proliferative activity and dysplasia in pancreatic intraepithelial neoplasia (PanIN): additional evidence for a recently proposed model of progression. Mod Pathol (2002) 2.33

Age-specific incidence of cancer: Phases, transitions, and biological implications. Proc Natl Acad Sci U S A (2008) 2.32

Recent advances on the molecular mechanisms involved in pancreatic cancer progression and therapies. Pancreas (2005) 2.23

APC mutations in colorectal tumors with mismatch repair deficiency. Proc Natl Acad Sci U S A (1996) 2.18

Selectively advantageous mutations and hitchhikers in neoplasms: p16 lesions are selected in Barrett's esophagus. Cancer Res (2004) 2.15

Cancer: drivers and passengers. Nature (2007) 2.11

Proliferation and turnover of glial cells in the forebrain of young adult mice as studied by repeated injections of 3 H-thymidine over a prolonged period of time. J Comp Neurol (1973) 2.03

Evolution of resistance and progression to disease during clonal expansion of cancer. Theor Popul Biol (2009) 1.97

A generalized Luria-Delbrück model. Math Biosci (2005) 1.72

Evolutionary dynamics of tumor suppressor gene inactivation. Proc Natl Acad Sci U S A (2004) 1.61

The evolution of two mutations during clonal expansion. Genetics (2007) 1.52

Multistage carcinogenesis: population-based model for colon cancer. J Natl Cancer Inst (1992) 1.38

The small intestine as a model for evaluating adult tissue stem cell drug targets. Cell Prolif (2003) 1.26

Cell kinetic analyses of human malignant brain tumors (gliomas). Cancer (1979) 1.21

The fixed-size Luria-Delbruck model with a nonzero death rate. Math Biosci (2007) 1.01

The breast cancer somatic 'muta-ome': tackling the complexity. Breast Cancer Res (2009) 0.98

Sequence-based advances in the definition of cancer-associated gene mutations. Curr Opin Oncol (2009) 0.84

The consensus coding sequences of human breast and colorectal cancers. Science (2006) 60.02

An integrated genomic analysis of human glioblastoma multiforme. Science (2008) 51.36

The genomic landscapes of human breast and colorectal cancers. Science (2007) 38.12

Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science (2008) 36.02

IDH1 and IDH2 mutations in gliomas. N Engl J Med (2009) 32.41

High frequency of mutations of the PIK3CA gene in human cancers. Science (2004) 27.94

Cancer genome landscapes. Science (2013) 25.33

Cancer genes and the pathways they control. Nat Med (2004) 24.22

Antibody neutralization and escape by HIV-1. Nature (2003) 21.48

Distant metastasis occurs late during the genetic evolution of pancreatic cancer. Nature (2010) 17.38

PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med (2015) 13.08

Transforming single DNA molecules into fluorescent magnetic particles for detection and enumeration of genetic variations. Proc Natl Acad Sci U S A (2003) 12.91

The colorectal microRNAome. Proc Natl Acad Sci U S A (2006) 11.59

Allelic variation in human gene expression. Science (2002) 11.42

Exome sequencing of head and neck squamous cell carcinoma reveals inactivating mutations in NOTCH1. Science (2011) 11.12

Frequent mutations of chromatin remodeling gene ARID1A in ovarian clear cell carcinoma. Science (2010) 10.78

Comparative lesion sequencing provides insights into tumor evolution. Proc Natl Acad Sci U S A (2008) 10.52

Circulating mutant DNA to assess tumor dynamics. Nat Med (2007) 10.33

DAXX/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors. Science (2011) 10.26

The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers. Nature (2012) 10.17

Quantitative analysis of culture using millions of digitized books. Science (2010) 9.86

DNMT1 and DNMT3b cooperate to silence genes in human cancer cells. Nature (2002) 9.40

A simple rule for the evolution of cooperation on graphs and social networks. Nature (2006) 9.31

Using the transcriptome to annotate the genome. Nat Biotechnol (2002) 9.04

Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci Transl Med (2014) 8.36

The genetic landscape of the childhood cancer medulloblastoma. Science (2010) 8.34

Mutant PIK3CA promotes cell growth and invasion of human cancer cells. Cancer Cell (2005) 7.87

Tumorigenesis: RAF/RAS oncogenes and mismatch-repair status. Nature (2002) 7.46

Exomic sequencing identifies PALB2 as a pancreatic cancer susceptibility gene. Science (2009) 7.39

TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal. Proc Natl Acad Sci U S A (2013) 6.88

Spontaneous giving and calculated greed. Nature (2012) 6.75

Dynamics of chronic myeloid leukaemia. Nature (2005) 6.63

The antisense transcriptomes of human cells. Science (2008) 6.29

Detection and quantification of rare mutations with massively parallel sequencing. Proc Natl Acad Sci U S A (2011) 6.29

Winners don't punish. Nature (2008) 6.12

Quantifying the evolutionary dynamics of language. Nature (2007) 6.12

Development of personalized tumor biomarkers using massively parallel sequencing. Sci Transl Med (2010) 6.08

Evolutionary dynamics on graphs. Nature (2005) 6.05

The structure of a human p110alpha/p85alpha complex elucidates the effects of oncogenic PI3Kalpha mutations. Science (2007) 6.01

Detection and quantification of mutations in the plasma of patients with colorectal tumors. Proc Natl Acad Sci U S A (2005) 5.91

Inactivation of hCDC4 can cause chromosomal instability. Nature (2004) 5.71

Mutational analysis of the tyrosine kinome in colorectal cancers. Science (2003) 5.43

Colorectal cancer: mutations in a signalling pathway. Nature (2005) 5.42

Glucose deprivation contributes to the development of KRAS pathway mutations in tumor cells. Science (2009) 5.31

Epitope landscape in breast and colorectal cancer. Cancer Res (2008) 5.29

A protocol for rapid generation of recombinant adenoviruses using the AdEasy system. Nat Protoc (2007) 5.15

Positive interactions promote public cooperation. Science (2009) 5.14

Via freedom to coercion: the emergence of costly punishment. Science (2007) 5.12

Recurrent GNAS mutations define an unexpected pathway for pancreatic cyst development. Sci Transl Med (2011) 5.03

Cancer-specific high-throughput annotation of somatic mutations: computational prediction of driver missense mutations. Cancer Res (2009) 4.92